This study is going to review therapeutic response to adalimumab (Cinnora) in patients with resistant IBD

In this interventional case series study, 20 confirmed cases of IBD were recruited between May 2020 and Sep 2020 in Guilan Province, north of Iran. These patients were under subcutaneously injection of adalimumab (made by CinnaGen Co.), 40 mg twice a day within 2 days and 80 milligrams in next two weeks. Patients were following up every three months in a year and they were checked out in term of laboratory tests, medication history, quality of life (IBDQ_9 questionnaire), drug side effects, drug reaction and response to treatment. Harvey-Bradshaw Index and Mayo score were used to evaluate Crohn’s disease (CD) and UC activity

In this study 3 patients were suffering from CD and 17 other were suffering from UC. Average age was between 41.20+15.97. Most of the participants (75%) were female and married. A majority were non-smokers (95%) and non-drinkers of alcohol (90%). About 70% of cases didn’t use fatty (full fat) diet and 70% of them were consuming high fiber diet. In 5% of patients developed cardiac, allergies and neurology side effects due to taking the drug. During the study patients had significant increase in scores of IBDQ_9 (P<0.001). Also based on Mayo and Harvey scores, the condition of patients with CD and UC was improved significantly (P<0.001). The mayo score were changed from moderate and severe (6/71) to mild (2/59). Harvey score was changed from moderate (14.67) to silence (2.33). Results from this study stated that amount of Cr, ALP, CRP, Hb, WBC, Calprotectin was closer to normal range after 12 months (P<0.001)

This indicates the effect of adalimumab (Cinnora) on the treatment of refractory inflammatory bowel disease